KRAS G12C
Clinical trials for KRAS G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C trials appear
Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First patients to receive experimental cancer drug in groundbreaking safety trial
Disease control Recruiting nowThis is the first-ever study in people to test a new cancer drug called TT125-802. The main goal is to find a safe dose and check for side effects in 50 adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will also look for early sig…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Apr 01, 2026 20:11 UTC
-
New drug targets multiple KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called BBO-11818 in people with advanced cancers that have specific KRAS gene mutations. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like lung, pancreatic, and colorectal cancer. Participants wil…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for pancreatic cancer patients: experimental immunotherapy offered outside clinical trial
Disease control AVAILABLEThis program provides access to an experimental immunotherapy called ELI-002 7P for patients with a specific type of pancreatic cancer (with KRAS or NRAS mutations) who are at high risk of the cancer coming back after surgery. It is for patients who have no other good treatment o…
Matched conditions: KRAS G12C
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for Tough-to-Treat lung cancer: first patients test novel drug
Disease control Recruiting nowThis is the first study in people to test a new drug called BBO-8520 for advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to find a safe dose and see if the drug can help shrink tumors. The study will test BBO-8520 alone …
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Personalized pills target root cause of painful vascular growths
Disease control Recruiting nowThis trial is testing two different oral medications for people with abnormal, non-cancerous growths of blood or lymph vessels (vascular malformations). The goal is to see if a year of treatment can reduce patients' most bothersome symptoms and shrink the growths. The specific dr…
Matched conditions: KRAS G12C
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New combo attack on lung cancer in the brain
Disease control Recruiting nowThis study is testing whether combining a targeted drug (adagrasib) with precise radiation to the brain (stereotactic radiosurgery) can better control lung cancer that has spread to the brain. It is for up to 30 adults with a specific type of advanced lung cancer (KRAS G12C-mutat…
Matched conditions: KRAS G12C
Phase: PHASE2 • Sponsor: Ryan Gentzler, MD • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New drug targets 'Undruggable' cancer mutation in early human trial
Disease control Recruiting nowThis study is testing a new drug called FMC-376 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe and effective dose and to see if the drug can shrink or control tumors. It is for patients whose cancer ha…
Matched conditions: KRAS G12C
Phase: PHASE1, PHASE2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC